Research Situation of Boron Neutron Capture Therapy Technology
نویسندگان
چکیده
منابع مشابه
Boron Neutron Capture Therapy
A project aimed at the development of an accelerator facility devoted to Boron Neutron Capture Therapy (BNCT) is ongoing at the National Atomic Energy Commission of Argentina [1]. In a first stage of development, the accelerator will be capable of delivering proton or deuteron beams of 30 mA at about 1.4 MeV which is suitable for neutron production through the 9Be(d,n) reaction. In this context...
متن کاملشبیه سازی چشمه 7li(p,n)7be جهت استفاده در bnct (boron neutron capture therapy)
با توجه به اینکه امروزه بیماران بسیاری در سراسر جهان از سرطان رنج میبرند،دانشمندان در تلاشند روشهای درمانی جدیدتر و بهتری را کشف کنند .یکی از این روشها "درمان بوسیله گیراندازی نوترون توسط بور (bnct)" نام دارد که میتواند یکی از بهترین روشهای مفید و موثر و جایگزین در درمان سرطانهایی از نوع glioblastoma و melanoma نسبت به روشهای متداولی چون شیمی درمانی یا رادیوتراپی باشد.در این روش هدف انجام واکنش...
Boron Neutron Capture Therapy of Cancer1
brain tumors. Shortly thereafter, a clinical trial was initiated at the Brookhaven National Laboratory in cooperation with Sweet and others at the Massachusetts General Hospital utilizing borax as the capture agent (5, 6). The objective at that time was to use BNCT as an adjunct to surgery for the treatment of patients with the most highly malignant and therapeutically refractory of all brain t...
متن کاملBoron Neutron Capture Therapy Treatment Planning Improvements
The Boron Neutron Capture Therapy (BNCT) treatment planning process of the Harvard/MIT team used for their clinical Phase I trials is very time consuming. If BNCT proves to be a successful treatment, this process must be made more efficient. Since the Monte Carlo treatment planning calculations were the most time consuming aspect of the treatment planning process, requiring more than thirty six...
متن کاملBoron neutron capture therapy for cancer.
*1102 Expression of Neural Cell Adhesion Molecule-related Sialoglycoprotein in Small Cell Lung Cancer and Neuroblastoma Cell Lines 1169 and CHP-212. C. E. C. Kitty Moolenaar. Egbert J. Muller, Dick J. Schol, Carl G. Figdor, Elizabeth Bock. Dieter Bitter-Suermann. and Rob J. A. M. Michalides. * 1107 Prolongation of Serum Half-Life of Interleukin 2 and Augmenta tion of Lymphokine-activated killer...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: DEStech Transactions on Social Science, Education and Human Science
سال: 2019
ISSN: 2475-0042
DOI: 10.12783/dtssehs/emse2018/27334